Kesimpta

Kesimpta Approved in EU as At-home Injectable Therapy for Relapsing MS

The European Commission has approvedĀ Novartisā€™ Kesimpta (ofatumumab) as the first self-administered, at-home B-cell-targeting therapy for adults with relapsing forms ofĀ multiple sclerosis (MS) and active disease. Active disease in these forms, which include clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS),…

Health Canada OKs Self-administered Kesimpta for Adults With Active RRMS

Health Canada has approvedĀ Kesimpta (ofatumumab) for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) who have active disease, as defined by clinical and imaging features. In contrast with other B-cell-targeting therapies used in MS, patients can self-administer a precise dose of Kesimpta at home using the Sensoready…

Survey: Patients, Nurses Prefer Sensoready Autoinjector Pen

People with multiple sclerosis (MS) and their nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta (ofatumumab) over other methods for injecting treatments, according to a survey. The survey was conducted by Novartis, which markets Kesimpta. Full findings from the survey will be presented at…

CHMP Favors Kesimpta for Adults With Relapsing MS in Europe

A branch of the European Medicines Agency (EMA) has recommended thatĀ Kesimpta (ofatumumab) be approved and made available to treat relapsing forms of multiple sclerosis (MS) in adults with active disease. A final decision from the European Commission (EC) is expected in about two months. Typically, the EC follows…

Ocrevus Still Reigns for Progressive MS, Spherix Reports, But Challenges Noted

Genentechā€™sĀ OcrevusĀ (ocrelizumab) continues to be the most prescribed treatment for people with progressive forms of multiple sclerosisĀ (MS) amongĀ U.S. neurologists, according to the latestĀ Spherix Global Insightsā€™ report. However, Novartisā€™Ā MayzentĀ (siponimod) ā€œis beginning to close the gapā€ with Ocrevus among those with active secondary progressive MS…

Rituximab Seen to Affect How B-cells Return After Treatment Stops

Rituximab, an investigational B-cell depletion therapy that target CD20 to treat people with multiple sclerosis (MS),Ā has significant effects on the characteristics of B-cells that return after treatment is stopped, with cells being less mature yet more activated toward a pro-inflammatory state, a study showed. Treatment also…

FDA Approves Kesimpta, B-cell Targeting Therapy for Relapsing MS

The U.S. Food and Drug Administration (FDA) has approved Novartis‘ Kesimpta (ofatumumab) as a self-administered treatment for adults with relapsing forms of multiple sclerosis (MS), meaning those withĀ clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS). According to Novartis,…